<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489147</url>
  </required_header>
  <id_info>
    <org_study_id>#FWA00015574</org_study_id>
    <nct_id>NCT04489147</nct_id>
  </id_info>
  <brief_title>Effect of Metformin on Non PCO Women Undergoing IVF/ICSI</brief_title>
  <official_title>Effect of Metformin on Non PCO Women Undergoing IVF/ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      400 Patients will be randomly assigned into two groups after informed consent from every&#xD;
      patient.&#xD;
&#xD;
      They will be classified into 2 groups:&#xD;
&#xD;
      Group A ( involves 200 patients ) will receive metformin 850 mg twice daily along the cycle&#xD;
      of Intra-cytoplasmic sperm injection (ICSI) Group B ( involve 200 patients) will not receive&#xD;
      metformin. They will undergo a cycle of ICSI. Primary outcome of this trial is to detect&#xD;
      occurrence of Ovarian Hyper-stimulation Syndrome (OHSS) , while secondary outcomes include&#xD;
      quality &amp; number of retrieved&#xD;
&#xD;
      follicles fertilization rate ,ongoing pregnancy rate &amp; endometrial thickness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-blinded (to the outcomes assessor), randomized controlled&#xD;
      trial conducted at the In Vitro Fertilization ( IVF) centers of the Departments of Obstetrics&#xD;
      &amp; Gynecology, Kasr El-Ainy Hospital and Beni-suef hospital in Cairo University and Beni-suef&#xD;
      university,respectively, Egypt, to determine the clinical effect of metformin on ICSI&#xD;
      outcomes in non PCO patients. Ethical committee approval was obtained. The study will include&#xD;
      400 infertile patients.&#xD;
&#xD;
      Inclusion criteria :&#xD;
&#xD;
        -  Patients subjected to IVF/ICSI aged 20-35 years with long agonist protocol&#xD;
&#xD;
        -  history of infertility for at least two years (either primary or secondary)&#xD;
&#xD;
        -  normal Thyroid stimulating Hormone (TSH) and prolactin&#xD;
&#xD;
      Exclusion criteria :&#xD;
&#xD;
        -  Patients who used metformin in the past 3-months before study&#xD;
&#xD;
        -  having medical problems such as kidney or liver diseases&#xD;
&#xD;
        -  Severe endometriosis.&#xD;
&#xD;
        -  hypo-thalamic amenorrhea.&#xD;
&#xD;
        -  Severe male factor( patients with testicular biopsy or those with azoo-spermia).&#xD;
&#xD;
        -  Associated uterine factor.&#xD;
&#xD;
        -  IVF/ ICSI for sex selection. All patients are informed about the study and consent is&#xD;
           given by those who accept to participate.&#xD;
&#xD;
      Careful history taking include infertility type, duration , cause, obstetric history, medical&#xD;
      and surgical history and demographic distribution is taken. Full physical examination and 2&#xD;
      dimensional (2D) transvaginal sonography (TVS) are done on day 2 to 5 of menses to assess&#xD;
      antral follicle count, uterus and adnexa . Body mass index (BMI) and waist/hip ratio (WHR)&#xD;
      are calculated, Blood samples are taken for AntiMullerian Hormone (AMH), Basal Follicle&#xD;
      Stimulating Hormone (FSH), Luteinizing Hormone (LH), Estradiol (E2), thyroid stimulating&#xD;
      hormone ( TSH), Prolactin and free testosterone.&#xD;
&#xD;
      All 400 participants will be randomized by withdrawing closed envelopes for each patient into&#xD;
      group A and group B .&#xD;
&#xD;
      Group A ( involves 200 patients ) will receive metformin 850 mg twice daily along the cycle&#xD;
      of ICSI Group B ( involve 200 patients) will not receive metformin.&#xD;
&#xD;
      They will undergo a cycle of ICSI.The agonist protocol is followed.Long protocol steps:&#xD;
&#xD;
        -  Start from day 19th - 20th by GnRH agonist ;Triptorelin 0.1mg subcutaneous (Decapeptyl,&#xD;
           Ferring). -1st visit : after 2 weeks of start of GnRH agonist or day 2 of cycle, we&#xD;
           confirm down regulation by a serum level of E2to be &lt;50 pg/ml, endometrial thickness&#xD;
           &lt;5mm, no ovarian cyst by ultrasound. Then we add Gonadotropins as Intramuscular (I.M.)&#xD;
           injections of 150-300 I.U. of highly purified Human Menopausal Gonadotropins daily&#xD;
           (Merional, 75 I.U. /vial, IBSA). The dose is adjusted according to the age, BMI, AFC,&#xD;
           serum levels of anti-mullerian hormone (AMH), follicle stimulating hormone (FSH) and&#xD;
           ovarian response.&#xD;
&#xD;
        -  2nd visit : on 6th - 7 th days of Gonadotrophins and then every other day to do&#xD;
           folliculometry by TVS and E2 level in serum.&#xD;
&#xD;
        -  We do trigger by Human Chorionic Gonadotrophin (HCG)10000 IU I.M.(Pregnyl, Organon) when&#xD;
           at least 3 follicles reach 18mm in mean diameter or more and E2 level is less than 2500&#xD;
           pg/ml. Ovum pickup is done 34 hours after HCG injection and embryo transfer using&#xD;
           Wallace catheter on day 2 to 3.&#xD;
&#xD;
             -  -Luteal support: Natural Progesterone 400 mg 1x2, Folic acid once daily,&#xD;
                Amoxicillin-Clavulanic Acid 1gm 1x2x7 ,Progesterone 100mg I.M. daily for 10 days,&#xD;
                Acetylsalicylic Acid once daily&#xD;
&#xD;
             -  -Quantitative ÃŸ- HCG in serum after 14 days of embryo transfer. -TVS to detect&#xD;
                clinical pregnancy at 6-7 weeks of gestation.&#xD;
&#xD;
      Primary outcome of this trial is to detect occurrence of Ovarian Hyper-stimulation Syndrome&#xD;
      (OHSS) , while secondary outcomes include quality &amp; number of retrieved follicles&#xD;
      fertilization rate ,ongoing pregnancy rate &amp; endometrial thickness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">November 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of OHSS</measure>
    <time_frame>4weeks</time_frame>
    <description>The number of cases of Ovarian Hyperstimulation Syndrome per cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of Mature retrieved eggs ( M-I) follicles .</measure>
    <time_frame>2-4weeks</time_frame>
    <description>The number of mature retrieved eggs (M-I) and each number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>4weeks</time_frame>
    <description>The number of fertilized eggs after injection with sperms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>number of pregnancies out of all ICSI cycles</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A ( involve 200 patients ) will receive metformin 850 mg twice daily along the cycle of ICSI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Metformin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group B ( involve 200 patients) will not receive metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin 850 mg orally twice daily along the cycle of ICSI</description>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients subjected to IVF/ICSI aged 20-35 years with long agonist protocol&#xD;
&#xD;
          -  history of infertility for at least two years (either primary or secondary)&#xD;
&#xD;
          -  normal TSH and prolactin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who used metformin in the past 3-months before study&#xD;
&#xD;
          -  having medical problems such as kidney or liver diseases&#xD;
&#xD;
          -  Severe endometriosis.&#xD;
&#xD;
          -  hypothalamic amenorrhea.&#xD;
&#xD;
          -  Severe male factor( patients with testicular biopsy or those with azoospermia).&#xD;
&#xD;
          -  Associated uterine factor.&#xD;
&#xD;
          -  IVF/ ICSI for sex selection.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amal Kotb, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Gabr, MD</last_name>
    <phone>00223682030</phone>
    <email>dr_amirarabi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beni-suef university hospital</name>
      <address>
        <city>Beni-sweif</city>
        <state>Beni-suef Governorate</state>
        <zip>62515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal Kotb, MD</last_name>
      <phone>0020822318605</phone>
      <email>amalkotb7295@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Amira S Dieb</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>non PCO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

